To our knowledge, this is the first reported case of osimertinib as salvage therapy in a NSCLC patient after aumolertinib resistance, providing a potential new strategy for treating patients with the EGFR T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.